89 related articles for article (PubMed ID: 10516101)
1. Kinetics of cyclocreatine and Na(+) cotransport in human breast cancer cells: mechanism of activity.
Maril N; Degani H; Rushkin E; Sherry AD; Cohn M
Am J Physiol; 1999 Oct; 277(4):C708-16. PubMed ID: 10516101
[TBL] [Abstract][Full Text] [Related]
2. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
3. Liposomal Delivery of Cyclocreatine Impairs Cancer Cell Bioenergetics Mediating Apoptosis.
Ganguly S; Elbayoumi T
Methods Mol Biol; 2021; 2275():173-186. PubMed ID: 34118038
[TBL] [Abstract][Full Text] [Related]
4. Cyclocreatine transport and cytotoxicity in rat glioma and human ovarian carcinoma cells: 31P-NMR spectroscopy.
Schiffenbauer YS; Meir G; Cohn M; Neeman M
Am J Physiol; 1996 Jan; 270(1 Pt 1):C160-9. PubMed ID: 8772441
[TBL] [Abstract][Full Text] [Related]
5. Hodgkin disease-derived cell lines expressing ubiquitous mitochondrial creatine kinase show growth inhibition by cyclocreatine treatment independent of apoptosis.
Kornacker M; Schlattner U; Wallimann T; Verneris MR; Negrin RS; Kornacker B; Staratschek-Jox A; Diehl V; Wolf J
Int J Cancer; 2001 Nov; 94(4):513-9. PubMed ID: 11745437
[TBL] [Abstract][Full Text] [Related]
6. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
7. In vivo (1)H MRS and (31)P MRSI of the response to cyclocreatine in transgenic mouse liver expressing creatine kinase.
Cui MH; Jayalakshmi K; Liu L; Guha C; Branch CA
NMR Biomed; 2015 Dec; 28(12):1634-44. PubMed ID: 26451872
[TBL] [Abstract][Full Text] [Related]
8. Cell cycle studies of cyclocreatine, a new anticancer agent.
Martin KJ; Winslow ER; Kaddurah-Daouk R
Cancer Res; 1994 Oct; 54(19):5160-5. PubMed ID: 7923134
[TBL] [Abstract][Full Text] [Related]
9. Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase.
Mulvaney PT; Stracke ML; Nam SW; Woodhouse E; O'Keefe M; Clair T; Liotta LA; Khaddurah-Daouk R; Schiffmann E
Int J Cancer; 1998 Sep; 78(1):46-52. PubMed ID: 9724093
[TBL] [Abstract][Full Text] [Related]
10. Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine.
Martin KJ; Vassallo CD; Teicher BA; Kaddurah-Daouk R
Anticancer Drugs; 1995 Jun; 6(3):419-26. PubMed ID: 7670140
[TBL] [Abstract][Full Text] [Related]
11. Phosphocyclocreatine is the dominant form of cyclocreatine in control and creatine transporter deficiency patient fibroblasts.
Gorshkov K; Wang AQ; Sun W; Fisher E; Frigeni M; Singleton M; Thorne N; Class B; Huang W; Longo N; Do MT; Ottinger EA; Xu X; Zheng W
Pharmacol Res Perspect; 2019 Dec; 7(6):e00525. PubMed ID: 31859463
[TBL] [Abstract][Full Text] [Related]
12. Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate.
LoPresti P; Cohn M
Biochim Biophys Acta; 1989 Oct; 998(3):317-20. PubMed ID: 2804134
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of rate of tumor growth by creatine and cyclocreatine.
Miller EE; Evans AE; Cohn M
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3304-8. PubMed ID: 8475072
[TBL] [Abstract][Full Text] [Related]
15. Cyclocreatine accumulation leads to cellular swelling in C6 glioma multicellular spheroids: diffusion and one-dimensional chemical shift nuclear magnetic resonance microscopy.
Schiffenbauer YS; Tempel C; Abramovitch R; Meir G; Neeman M
Cancer Res; 1995 Jan; 55(1):153-8. PubMed ID: 7805026
[TBL] [Abstract][Full Text] [Related]
16. Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts.
Uemura T; Ito S; Masuda T; Shimbo H; Goto T; Osaka H; Wada T; Couraud PO; Ohtsuki S
Pharm Res; 2020 Mar; 37(3):61. PubMed ID: 32124083
[TBL] [Abstract][Full Text] [Related]
17. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
18. Electrophysiology and biochemical analysis of cyclocreatine uptake and effect in hippocampal slices.
Enrico A; Patrizia G; Luisa P; Alessandro P; Gianluigi L; Carlo G; Maurizio B
J Integr Neurosci; 2013 Jun; 12(2):285-97. PubMed ID: 23869866
[TBL] [Abstract][Full Text] [Related]
19. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
[TBL] [Abstract][Full Text] [Related]
20. Creatine and cyclocreatine effects on ischemic myocardium: 31P nuclear magnetic resonance evaluation of intact heart.
Osbakken M; Ito K; Zhang D; Ponomarenko I; Ivanics T; Jahngen EG; Cohn M
Cardiology; 1992; 80(3-4):184-95. PubMed ID: 1511465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
